Structure of oral reversible ERK1/2 kinase inhibitor AZD0364

oral reversible ERK1/2 kinase inhibitor

combo eff. w/ MEKi in mKRAS model; in Ph. I

from historical kinase sel. data, SBDD + opt.

Mol. Cancer Ther. Dec. 3, 2020

AstraZeneca, Cambridge, UK

AstraZeneca oral reversible ERK1/2 kinase inhibitor


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.